Miho Shinmura

Title: Miho Shinmura: Innovator in Botulinum Toxin Research

Introduction

Miho Shinmura is a prominent inventor based in Kumamoto, Japan. She has made significant contributions to the field of botulinum toxin research, holding 2 patents that focus on innovative methods for treating patients with muscle overactivity.

Latest Patents

One of her latest patents is a method for treating patients who have developed a neutralizing antibody to type A1 botulinum toxin. This method involves administering a 150 kDa type A neurotoxin from type A2 (A2 NTX) to the patient. This invention addresses the clinical response decrease caused by the neutralizing antibody, providing a new therapeutic approach. Another notable patent involves a novel type A toxin preparation, which serves as a neuromuscular transmission blocking agent. This preparation is derived from the infant botulism pathogen and is designed to treat diseases characterized by muscle overactivity. Compared to conventional toxin preparations, this medicament offers rapid efficacy and a broader safety margin, making it a promising option for therapeutic use.

Career Highlights

Miho Shinmura has worked with esteemed institutions such as the Chemo-Sero-Therapeutic Research Institute and Tokushima University. Her work in these organizations has allowed her to advance her research and contribute to the scientific community.

Collaborations

Some of her notable coworkers include Yasushi Torii and Yoshitaka Goto, who have collaborated with her on various research projects.

Conclusion

Miho Shinmura's innovative work in botulinum toxin research has the potential to significantly impact the treatment of muscle overactivity. Her patents reflect her dedication to advancing medical science and improving patient outcomes.